Medy-Tox Inc. (KOSDAQ: 086900)

Market Cap	829.97B
Revenue (ttm)	246.25B
Net Income (ttm)	4.59B
Shares Out	6.73M
EPS (ttm)	670.87
PE Ratio	183.79
Forward PE	19.20
Dividend	1,100.00 (0.87%)
Ex-Dividend Date	Sep 27, 2024

Volume	47,636
Open	122,900
Previous Close	125,900
Day's Range	122,600 - 126,400
52-Week Range	122,000 - 256,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 703
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2023, Medy-Tox's revenue was 221.12 billion, an increase of 13.34% compared to the previous year's 195.10 billion. Earnings were 8.78 billion, a decrease of -75.63%.